HEPATIC PLASMINOGEN LOWERING WITH RNA INTERFERENCE FOR THE TREATMENT OF BLEEDING DISORDERS IS UNLIKELY TO POSE THROMBOTIC RISK BASED ON UK BIOBANK ANALYSES AND MOUSE MODELS OF PROVOKED THROMBOSIS
EHA Library, Rodney Camire, 4159393
CORD RED BLOOD CELL TRANSFUSIONS IN EXTREMELY LOW GESTATIONAL AGE NEONATES TO PREVENT SEVERE ROP: RESULTS OF THE RANDOMIZED CLINICAL TRIAL BORN
EHA Library, Claudio Pellegrino, 4159384
TARGETING THE MTOR PATHWAY TO REGULATE PIEZO1-MEDIATED IRON OVERLOAD
EHA Library, Federica Maria Esposito, 4159383
IRON TRAPPING IN MACROPHAGES RESHAPES THE HOMEOSTASIS OF THE HAEMATOPOIETIC SYSTEM
EHA Library, Laura Crisafulli, 4159382
INVASIVE FUNGAL INFECTIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY RESULTS OF A MULTICENTRIC PROSPECTIVE SEIFEM STUDY (ALL-IFI)
EHA Library, Chiara Cattaneo, 4159381
INCIDENCE AND RISK FACTORS FOR LATE CYTOMEGALOVIRUS (CMV) BLOOD INFECTIONS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALLOHCT)
EHA Library, George Chen, 4159380
LONG TERM FOLLOW UP OF THE BATMO PROTOCOL (BEST-ANTIMICROBIAL-THERAPY-TMO) AND COMPARISON WITH HYSTORICAL DATA
EHA Library, Michele Malagola, 4159378
G-CSF IMPROVES TREG SELECTION AND OUTCOMES OF HLA-HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH T CELL ADOPTIVE IMMUNOTHERAPY
EHA Library, Rebecca Sembenico, 4159341
POOLED FECAL ALLOGENIC MICROBIOTHERAPY FOR REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE : RESULTS FROM THE EARLY ACCESS PROGRAM IN EUROPE
EHA Library, Mohamad Mohty, 4159337
HIGH CD70 EXPRESSION IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA IS LINKED TO RELAPSE AND PRESENTS OPPORTUNITIES FOR DUAL CD19-CD70 CAR-T THERAPY
EHA Library, Maria Ros, 4159315
LONG-TERM EFFICACY AND SURVIVAL OUTCOMES WITH ODRONEXTAMAB FOR PATIENTS (PTS) WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL): 2-YEAR FOLLOW-UP FROM THE PHASE 2 ELM-2 STUDY
EHA Library, Stefano Luminari, 4159312
GENOMIC PROFILING FOR CLINICAL DECISION MAKING IN POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS.
EHA Library, Barbara Mora, 4159296
IDENTIFYING AN ULTRA-POOR RISK ' MAYO STAGE IIIC' GROUP IN SYSTEMIC AL AMYLOIDOSIS IN THE DARATUMUMAB-ERA: A EUROPEAN COLLABORATION
EHA Library, Jahanzaib Khwaja, 4159275
CLINICAL CHARACTERISTICS AND SURVIVAL OF 312 PATIENTS WITH MPL-MUTANT ESSENTIAL THROMBOCYTHEMIA: AN INTERNATIONAL EUROPEAN LEUKEMIANET COLLABORATIVE STUDY
EHA Library, Steffen Koschmieder, 4159292
THE REVISED MUTATION-ADJUSTED RISK SCORE (MARS-R) FOR PREDICTING OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH MIDOSTAURIN OR AVAPRITINIB
EHA Library, Johannes Lübke, 4159293
NEUTROPHIL-TO LYMPHOCYTE RATIO AS A SURROGATE INFLAMMATORY BIOMARKER FOR JAK2V617F SUPPRESSION AND EVENT-FREE SURVIVAL IN POLYCYTHEMIA VERA
EHA Library, Tiziano Barbui, 4159294
CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB AND ANEMIA SUPPORTING MEDICATIONS
EHA Library, Pankit Vachhani, 4159295
CIRCULATING TUMOR CELLS FOR THE STAGING OF MULTIPLE MYELOMA: A EUROPEAN POOLED ANALYSIS OF 2446 NEWLY DIAGNOSED PATIENTS
EHA Library, Luca Bertamini, 4159276
MULTIOMIC CHARACTERIZATION OF CLONOTYPIC B CELLS IN PATIENTS (PTS) WITH LIGHT-CHAIN AMYLOIDOSIS (AL) AND MULTIPLE MYELOMA (MM)
EHA Library, Carmen Gonzalez, 4159274
ELEVATED CIRCULATING TUMOR CELL (CTC) NUMBERS ASSOCIATE WITH A HIGHLY PROLIFERATIVE (PR) AND GENOMICALLY COMPLEX PHENOTYPE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS
EHA Library, Juan-Jose Garces, 4159273
VENOUS THROMBOEMBOLISM IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: INSIGHTS FROM REAL-WORLD DATA
EHA Library, Vladimir Otasevic, 4159396
TARGETED SUPPRESSION OF EFFECTOR T CELLS BY GPIBα CAAR-TREG CELLS IN REFRACTORY/RELAPSED IMMUNE THROMBOCYTOPENIA
EHA Library, Jinhui Shu, 4159395
MICROFLUIDIC TESTING USING THE MAASTRICHT FLOWCHAMBER IN PATIENTS WITH BLEEDING DISORDER OF UNKNOWN CAUSE (BDUC)
EHA Library, Amaury Monard, 4159394
A PHASE 1 STUDY OF KITE-363 ANTI-CD19/CD20 CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA
EHA Library, Saurabh Dahiya, 4159313
REAL-WORLD EFFECTIVENESS AND SAFETY OUTCOMES AMONG KEY SUBGROUPS OF SECOND-LINE (2L) AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)
EHA Library, Dasom Lee, 4159314
A GLOBAL PHASE 1B STUDY OF JNJ-90014496, A CD19/CD20 BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)
EHA Library, Matthew Ku, 4159316
BLASTS- AND MODIFIED EASIX-GUIDED RISK STRATIFICATION FOR CAR-T-ASSOCIATED COAGULOPATHY AND OUTCOMES
EHA Library, Yingying Li, 4159392
SAFETY OF HYPOXIC RED BLOOD CELL ADMINISTRATION IN PATIENTS WITH TRANSFUSION-DEPENDENT HEMATOLOGICAL MALIGNANCIES
EHA Library, Håkon Reikvam, 4159386
BLOOD GROUP GENOTYPE DIVERSITY IN SICKLE CELL DISEASE PATIENTS: ANTIGENIC PROFILE FROM A SINGLE CENTER AND SYSTEMATIC REVIEW OF THE LITERATURE
EHA Library, Luiza Francisco Trafane, 4159385
CHANGES IN THE SPECTRUM AND PROGNOSIS OF INVASIVE FUNGAL DISEASES IN CZECH, SLOVAK, AND CROATIAN HEMATOLOGY CENTERS FROM 2000 TO 2023 - FIND ANALYSIS
EHA Library, Barbora Weinbergerová, 4159379
AUTONOMOUS AI-DRIVEN INTENSIFIED PROPHYLAXIS OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE IN HAPLOIDENTICAL TRANSPLANTS: A SINGLE-CENTRE, PROOF-OF-CONCEPT, PHASE 2 TRIAL
EHA Library, Yigeng Cao, 4159338
ANTI-CD25 ANTIBODY AS AN ALTERNATIVE TO METHOTREXATE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS RESULTED IN BETTER OUTCOMES IN PATIENT OF CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY BRIDGING TO TRANSPLANT
EHA Library, Zhihui Li, 4159339
PHARMACOKINETIC-GUIDED ATG DOSING OPTIMIZES OUTCOMES IN MYELOABLATIVE HAPLO-CORD HCT
EHA Library, Qingya cui, 4159340
REAL-WORLD INSIGHT ON TREATMENT WITH MARIBAVIR FOR CLINICALLY-SIGNIFICANT CMV INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: A RETROSPECTIVE INTERNATIONAL IDWP EBMT STUDY
EHA Library, Annalisa Paviglianiti, 4159377
RANKL CYTOKINE IS A NOVEL SUPPORTIVE SIGNAL IN THE BONE MARROW HEMATOPOIETIC NICHE
EHA Library, Francesca Ficara, 4159351
EPITOPE EDITING ENABLES IMMUNE-BASED SELECTION OF MULTIPLEX GENOME ENGINEERED STEM CELLS AND IMPROVED NON-GENOTOXIC CONDITIONING
EHA Library, Gabriele Casirati, 4159352
TYPE I INTERFERON IMPAIRS CAR-T CELL FUNCTION BY DISRUPTING IMMUNE SYNAPSE ASSEMBLY
EHA Library, Meijuan Huang, 4159354
IPSC-DERIVED CD2-TARGETED CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY FOR T CELL MALIGNANCIES
EHA Library, Shintaro Kinoshita, 4159356
LONG-TERM EFFICACY AND SAFETY STUDY OF RILZABRUTINIB, ORAL BRUTON TYROSINE KINASE INHIBITOR, IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA (WAIHA): LUMINA PHASE 2B PART B
EHA Library, Bruno Fattizzo, 4159375
THREE-YEAR SAFETY, EFFICACY, AND RENAL OUTCOMES OF MITAPIVAT TREATMENT IN SICKLE CELL DISEASE: RESULTS FROM A PHASE 2, OPEN-LABEL STUDY
EHA Library, Geoffrey Kuppens, 4159376
TGF-ß1-TRIGGERED MALADAPTIVE BONE MARROW ENDOTHELIUM IMPEDES HEMATOPOIETIC RECOVERY
EHA Library, Zhong-Shi Lyu, 4159350
WHO IS THE BEST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT DONOR FOR SEVERE APLASTIC ANEMIA? A MULTICENTER RETROSPECTIVE EXPERIENCE FROM CHINA.
EHA Library, Xiao-Di Ma, 4159335
REPRESSION OF MIR-29 VIA MYC LEADS TO INCREASED CD40 SIGNALING IN TRANSFORMED FOLLICULAR LYMPHOMA (FL) AND UNFAVOURABLE PROGNOSIS IN FL
EHA Library, Daniel Filip, 4159330
PERIPHERAL T-CELL LYMPHOMAS IN THE ELDERLY: REPORT ON 922 PATIENTS FROM THE T-CELL PROJECT 1.0 AND 2.0.
EHA Library, Tetiana Skrypets, 4159321
PROSPECTIVE VALIDATION OF END OF TREATMENT CTDNA-MRD BY PHASED-SEQ IN DLBCL PATIENTS FROM A NATIONAL HOVON TRIAL
EHA Library, Martine Chamuleau, 4159317
ELEVATED SERUM TARC AFTER ONE CYCLE OF BV-AVD CORRELATES WITH ADVERSE PROGNOSIS DESPITE ESCALATION TO BRECADD IN ADVANCED STAGE HODGKIN LYMPHOMA: BIOMARKER ANALYSIS FROM THE EORTC-1537-COBRA TRIAL
EHA Library, Sophie Teesink, 4159306
BRECADD: THE OPTIMAL TREATMENT FOR ADVANCED-STAGE HODGKIN LYMPHOMA — A METANALYSIS AND AN INDIRECT COMPARISON WITH INDIVIDUAL PATIENT DATA EXTRACTION
EHA Library, Andrea Visentin, 4159304
SANRECO, AN ON-GOING PHASE1/2 STUDY EVALUATING DIVESIRAN, A NOVEL GALNAC-CONJUGATED SIRNA, IN PATIENTS WITH POLYCYTHEMIA VERA
EHA Library, Marina Kremyanskaya, 4159301
THROMBOTIC ADVERSE EVENTS IN PATIENTS RECEIVING THROMBOPOIETIN RECEPTOR AGONISTS: A EUROPEAN MULTICENTER STUDY
EHA Library, Maria Lozano, 4159401
A PHENOME-WIDE ASSOCIATION STUDY (PHEWAS) OF ADAMTS13 VARIANTS YIELDS INSIGHT INTO THE EFFECT OF ADAMTS13 MUTATIONS
EHA Library, Matthew Carter, 4159400
AZACITIDINE, VENETOCLAX, AND REVUMENIB FOR NEWLY DIAGNOSED OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA (AML) AND NPM1 MUTATION OR KMT2A REARRANGEMENT: UPDATED RESULTS FROM THE BEAT AML CONSORTIUM
EHA Library, Joshua Zeidner, 4159215
THE INTERPLAY BETWEEN INFLAMMATION AND IMMUNE ESCAPE IN MDS WITH P53 DYSFUNCTION EVOLUTION: INSIGHTS FROM SINGLE-CELL MULTI-OMICS
EHA Library, Matteo Zampini, 4159248
DEVELOPMENT OF NOVEL CCL2-DRUG CONJUGATES FOR THE TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKAEMIA
EHA Library, Rachel Cant, 4159249
IN MULTIPLE MYELOMA, DEL17P CONFERS VULNERABILITY TO THE INHIBITION OF PKMYT1 KINASE.
EHA Library, Anaïs Schavgoulidze, 4159264
CYCLOPHOSPHAMIDE IS SUPERIOR TO METHOTREXATE IN PREVIOUSLY UNTREATED LARGE GRANULAR LYMPHOCYTE LEUKEMIA. FINAL RESULTS OF A PROSPECTIVE, MULTICENTRIC, PHASE II RANDOMIZED CONTROLLED TRIAL CT01976182.
EHA Library, Thierry Lamy, 4159267
THE TRIPLE COMBINATION OF VENETOCLAX-IBRUTINIB-OBINUTUZUMAB PROLONGS PROGRESSION-FREE SURVIVAL COMPARED TO VENETOCLAX-CD20-ANTIBODY COMBINATIONS AND CHEMOIMMUNOTHERAPY IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: FINAL ANALYSIS FROM THE PHASE 3 GAIA/CLL13 TRIAL
EHA Library, Moritz Fürstenau, 4159268
LONG-TERM (≥5 YEAR) REMISSION AND SURVIVAL AFTER TREATMENT WITH CILTACABTAGENE AUTOLEUCEL IN CARTITUDE-1 PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Library, Sundar Jagannath, 4159269
CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) AS MAINTENANCE THERAPY AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
EHA Library, Dominik Dytfeld, 4159270
PELABRESIB IN COMBINATION WITH RUXOLITINIB FOR JANUS KINASE INHIBITOR-NAIVE PATIENTS WITH MYELOFIBROSIS: 72-WEEK FOLLOW-UP WITH LONG-TERM EFFICACY OUTCOMES OF THE PHASE III MANIFEST-2 STUDY
EHA Library, Alessandro Vannucchi, 4159300
ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-RISK MYELOFIBROSIS
EHA Library, Harinder Gill, 4159299
PRELIMINARY DATA FROM PHASE I/II STUDY OF NUVISERTIB, AN ORAL INVESTIGATIONAL SELECTIVE PIM1 INHIBITOR, SHOWED CLINICAL RESPONSE CORRELATING WITH CYTOKINE MODULATION IN PATIENTS WITH MYELOFIBROSIS
EHA Library, Lindsay Rein, 4159298
HEMATOLOGICAL IMPROVEMENT AND OTHER CLINICAL BENEFITS OF ELRITERCEPT AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB IN PARTICIPANTS WITH MYELOFIBROSIS (MF) FROM THE ONGOING PHASE 2 RESTORE TRIAL
EHA Library, Timothy Devos, 4159297
CARFILZOMIB INDUCTION, CONSOLIDATION, AND MAINTENANCE WITH OR WITHOUT AUTOLOGOUS STEM-CELL TRANSPLANT: LONG-TERM FOLLOW-UP OF THE RANDOMISED, PHASE 2 FORTE TRIAL
EHA Library, Francesca Gay, 4159271
ACIMTAMIG (AFM13) IN COMBINATION WITH ALLONK® (AB-101) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM THE DOSE FINDING PHASE OF THE LUMINICE-203 PHASE 2 STUDY
EHA Library, Joseph Maakaron, 4159302
LONG-TERM RESPONSES AND LATE TOXICITIES IN ADVANCED-STAGE HODGKIN LYMPHOMA: A 10-YEAR UPDATE OF THE HD0607 TRIAL
EHA Library, Alessandro Cellini, 4159303
THE ROLE OF STEM CELL TRANSPLANTATION AS CONSOLIDATION THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH CHECKPOINT INHIBITORS: ITALIAN MULTICENTER EXPERIENCE
EHA Library, Elise Lucchini, 4159305
TARGETING C-MYC MRNA WITH RIBOTAC: A NOVEL STRATEGY FOR MYELOMA TREATMENT IN VITRO AND IN VIVO
EHA Library, Domenico Maisano, 4159266
ENHANCER EXTRACHROMOSOMAL CIRCULAR DNA ANKRD28 DRIVES DRUG RESISTANCE VIA POU2F2-MEDIATED TRANSCRIPTIONAL REWIRING IN MULTIPLE MYELOMA
EHA Library, Binzhen Chen, 4159265
FRAIL IS NOT FAIL: COMORBIDITIES DO NOT AFFECT NON-RELAPSE MORTALITY AND SAFETY IN PATIENTS WITH LBCL TREATED WITH CAR-T THERAPY
EHA Library, Eugenio Galli, 4159318
THERAPEUTIC OUTCOMES IN T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL): A COLLABORATIVE MULTI-CENTER STUDY COHORT AND GENOMIC ANALYSIS
EHA Library, Jonathan Brammer, 4159319
OUTCOMES IN AN INTERNATIONAL MULTICENTRE STUDY OF 600 PATIENTS WITH CNS RELAPSE OF LARGE B CELL LYMPHOMA: COMPARTMENT OF RELAPSE IS PROGNOSTIC
EHA Library, Diva Baggio, 4159320
SINGLE CELL ANALYSIS REVEALS EXTENSIVE IMMUNE EXHAUSTION AND MEMORY-CELL LIKE ORIGIN IN FOLLICULAR LYMPHOMA WITH INCREASED IRF4 EXPRESSION
EHA Library, Patrizia Mondello, 4159327
MULTI-OMICS DISSECTION OF EBV-DRIVEN HETEROGENEITY, METABOLIC REMODELING, AND TUMOR CELLULAR LANDSCAPE IN ENKTL PROGRESSION
EHA Library, Jinhua Liang, 4159328
PTPN2 INHIBITION DISRUPTS MITOCHONDRIAL RENEWAL AND BLOCKS TFRC-MEDIATED PINK1-PRKN-DEPENDENT MITOPHAGY TO EXERT ANTI-TUMOR ACTIVITIES IN ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA.
EHA Library, Jinhua Liang, 4159329
TITLE: TRANSCRIPTIONAL AND PROTEOMIC LANDSCAPE OF EBV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA: GENOMIC AND VIRAL FACTORS DRIVING AN IMMUNOTOLERANT NICHE
EHA Library, Axel Künstner, 4159331
JAK/ROCK INHIBITION WITH ROVADICITINIB SUPPRESSES MURINE AND HUMAN ACUTE GRAFT-VERSUS-HOST DISEASE: THE RESULTS OF PRECLINICAL AND PHASE 1B STUDY
EHA Library, Yanmin Zhao, 4159332
TARGETED DOSING OF ANTI-THYMOCYTE GLOBULIN VERSUS FIXED DOSING STRATEGY IN PATIENTS UNDERGOING UNMANIPULATED HAPLOIDENTICAL HAEMATOPOIETIC STEM-CELL TRANSPLANTATION: A RANDOMIZED, MULTICENTER, PHASE 3 CLINICAL TRIAL
EHA Library, Dai-Hong Liu, 4159333
THE RANDOMIZED CONTROLLED HAMLET TRIAL SHOWS NO SURVIVAL DIFFERENCE BETWEEN HAPLOIDENTICAL RELATED AND SINGLE HLA-LOCI MISMATCHED UNRELATED DONOR TRANSPLANTATION IN PATIENTS WITH HIGH RISK AML/ALL/MDS
EHA Library, Johannes Schetelig, 4159334
COMPARABLE SURVIVAL OUTCOMES IN HLA-MATCHED AND HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA PATIENTS AGED 40-50: A CBMTR REGISTRY-BASED PSM ANALYSIS OVER THE LAST DECADE
EHA Library, Lan-Ping Xu, 4159336
MULTIOMICS CHARACTERIZATION OF MINIMAL RESIDUAL DISEASE (MRD) KINETICS IN MULTIPLE MYELOMA (MM) PATIENTS REVEALS THAT EARLY IMMUNOTHERAPY INTERCEPTION DRIVES CLINICAL BENEFIT IN EXPERIMENTAL MODELS
EHA Library, Noelia Collado-Gisbert, 4159263
INTEGRATIVE MULTIOMIC ANALYSIS OF MULTIPLE MYELOMA IDENTIFIES MOLECULAR PREDICTORS OF MRD IN THE MIDAS TRIAL
EHA Library, Stéphane Minvielle, 4159262
DISCOVERY OF ATP2B1+ CD49F+ HUMAN HEMATOPOIETIC STEM CELLS WITH SUPERIOR LONG-TERM MULTILINEAGE RECONSTITUTION
EHA Library, Angelica Varesi, 4159347
THE B-ALL STROMAL LANDSCAPE: SPATIAL ORGANIZATION AND FUNCTIONAL SPECIALIZATION OF DISTINCT NICHE SUBTYPES
EHA Library, Mauricio Ferrao Blanco, 4159348
ENHANCE THE THERAPEUTIC EFFICACY OF HUMAN UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS IN PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE THROUGH CRISPLD2 MODULATION
EHA Library, Xu Qing, 4159349
A FUNCTIONAL CAR-T CELL ATLAS TO UNRAVEL REGULATORY MECHANISMS OF CAR-T CELLS
EHA Library, Juan Rodriguez-Madoz, 4159353
PRECLINICAL DEVELOPMENT OF CCR4 CAR T CELLS FOR THE TREATMENT OF T-NHL
EHA Library, Marissa Del Real, 4159355
NMNAT3 DEFICIENCY: A NOVEL RED BLOOD CELL ENZYMOPATHY
EHA Library, Titine Ruiter, 4159372
EFFICACY AND SAFETY OF MITAPIVAT IN PEDIATRIC PATIENTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE REGULARLY TRANSFUSED: RESULTS FROM THE PHASE 3 RANDOMIZED GLOBAL PLACEBO-CONTROLLED ACTIVATE-KIDST TRIAL
EHA Library, Rachael Grace, 4159373
SATISFY: MITAPIVAT IN ADULTS WITH ERYTHROCYTE MEMBRANOPATHIES AND CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE II: A EUROBLOODNET, MULTICENTER, SINGLE-ARM, PHASE 2 STUDY
EHA Library, Thomas Doeven, 4159374
RVU120 ENHANCES ERYTHROID POTENTIAL IN MDS PATIENT-DERIVED CELLS: PRECLINICAL MECHANISTIC INSIGHTS INTO CDK8/CDK19 INHIBITION AND POTENTIAL PATIENT STRATIFICATION
EHA Library, Milena Mazan, 4159251
ACTIVATION OF GENOMIC REGIONS DRIVEN BY PU.1 DISTINGUISHES LOW-RISK MDS SUBSETS CHARACTERIZED BY IMMUNE DYSREGULATION AND PROGRESSION
EHA Library, Veronica Vallelonga, 4159250
SINGLE-CELL ATLAS OF PEDIATRIC NRAS-MUTANT MYELOID NEOPLASMS REVEALS MYELOID LINEAGE BIAS AND IDENTIFIES POTENTIAL THERAPEUTIC TARGETS
EHA Library, Suyu Zong, 4159247
TUSCANY STUDY OF SAFETY AND EFFICACY OF TUSPETINIB PLUS STANDARD OF CARE VENETOCLAX AND AZACITIDINE IN STUDY PARTICIPANTS WITH NEWLY DIAGNOSED AML INELIGIBLE FOR INDUCTION CHEMOTHERAPY
EHA Library, Rafael Bejar, 4159216
RP2D DETERMINATION OF BLEXIMENIB IN COMBINATION WITH VEN+AZA: PHASE 1B STUDY IN ND & R/R AML WITH KMT2A/NPM1 ALTERATIONS
EHA Library, Andrew H. Wei, 4159214
ZIFTOMENIB COMBINED WITH INTENSIVE INDUCTION CHEMOTHERAPY (7+3) IN NEWLY DIAGNOSED NPM1-M OR KMT2A-R ACUTE MYELOID LEUKEMIA (AML): UPDATED PHASE 1A/B RESULTS FROM KOMET-007
EHA Library, Harry Erba, 4159213
ALL-ORAL DECITABINE-CEDAZURIDINE (DEC-C) + VENETOCLAX (VEN) IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) INELIGIBLE FOR INDUCTION CHEMOTHERAPY: PHASE 1/2 CLINICAL TRIAL RESULTS
EHA Library, Gail Roboz, 4159212
SPLANCHNIC VEIN THROMBOSIS IN MYELOPROLIFERATIVE NEOPLASMS: UPDATED ANALYSIS OF ANTICOAGULATION MANAGEMENT AND OUTCOMES IN A GLOBAL ABDOMINAL/SPLANCHNIC VEIN THROMBOSIS RETROSPECTIVE OBSERVATIONAL STUDY IN 889 MPN PATIENTS (GASTRO-MPN)
EHA Library, Mandy Lauw, 4159397
INCIDENCE AND CLINICAL OUTCOMES OF ERYTHROCYTOSIS ASSOCIATED WITH SGLT-2 INHIBITORS: A SINGLE-CENTER RETROSPECTIVE STUDY
EHA Library, Ji Yun Lee, 4159398
SPLANCHNIC VEIN THROMBOSIS WITH AND WITHOUT MYELOPROLIFERATIVE NEOPLASMS: A COMPARATIVE COHORT STUDY
EHA Library, Amica Ko, 4159399
THE QUALITY OF LIFE OF ACUTE LEUKEMIA PATIENTS AND THE CURRENT STATUS OF ANTICIPATORY GRIEF REACTIONS AMONG THEIR PRIMARY FAMILY CAREGIVERS, ALONG WITH AN ANALYSIS OF INFLUENCING FACTORS.
EHA Library, LI GAO, 4162884

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings